Department of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, PR China.
Phytomedicine. 2013 Jul 15;20(10):820-7. doi: 10.1016/j.phymed.2013.03.027. Epub 2013 May 10.
Breviscapine is a flavonoid extracted from a Chinese herb Erigeron breviscapus, previously it was shown that treatment with breviscapine attenuated renal injury in the diabetic rats. The purpose of this study was to investigate whether breviscapine combined with enalapril (an ACE inhibitor) have superior renoprotective effects against diabetic nephropathy. Rats were randomly separated into five groups: control, diabetes, diabetes treated with enalapril, diabetes treated with breviscapine, or diabetes treated with combined enalapril with breviscapine. Twenty-four hours urinary AER and the levels of 3-NT in renal tissue and MDA in renal tissue and urine as well as activities and expression of PKC in renal tissue were determined, and renal tissue morphology were observed by light microscopy after 8 weeks. Expression of TGFβ1 protein was performed by immunohistochemistry method. Increased AER and kidney pathologic injury were attenuated by treatment with either enalapril or breviscapine and further reduced by the combination of the two. Elevated 3-NT in renal tissue and MDA levels in renal tissue and urine were reduced by enalapril or breviscapine and, more effectively, by combined enalapril with breviscapine. PKC activities and expression were higher in renal tissue in diabetic rats than those of the control group, which were reduced by both monotherapies, and further abrogated by combination therapy in both cases. Overexpression of TGFβ1 protein observed in the glomeruli and tubulointerstitium of diabetic rats was attenuated by enalapril or breviscapine to a similar lever and further reduced by the combination of the two. The combination of enalapril and breviscapine confers superiority over monotherapies on renoprotection, which mechanism may be at least partly correlated with synergetic suppression on increased oxidative stress and PKC activities as well as overexpression of TGFβ1 in renal tissue.
灯盏花素是从一种中国草药灯盏细辛中提取的黄酮类化合物,先前的研究表明,灯盏花素治疗可减轻糖尿病大鼠的肾损伤。本研究旨在探讨灯盏花素联合依那普利(一种 ACE 抑制剂)对糖尿病肾病是否具有更好的肾保护作用。大鼠随机分为五组:对照组、糖尿病组、糖尿病依那普利治疗组、糖尿病灯盏花素治疗组和糖尿病联合依那普利与灯盏花素治疗组。8 周后测定 24 小时尿 AER 和肾组织 3-NT 水平及肾组织和尿 MDA 水平以及肾组织 PKC 活性和表达,并通过光镜观察肾组织形态。采用免疫组化法检测 TGFβ1 蛋白的表达。依那普利或灯盏花素治疗可减轻 AER 增加和肾脏病理损伤,并进一步降低两者的结合。肾组织 3-NT 升高和 MDA 水平升高以及尿 MDA 水平降低,依那普利或灯盏花素治疗更为有效,联合依那普利与灯盏花素治疗效果更佳。糖尿病大鼠肾组织 PKC 活性和表达高于对照组,两种药物单独治疗均可降低,联合治疗可进一步降低。糖尿病大鼠肾小球和肾小管间质 TGFβ1 蛋白过度表达可被依那普利或灯盏花素治疗减轻,两种药物联合治疗效果更佳。依那普利和灯盏花素联合治疗对肾保护具有优势,其机制至少部分与协同抑制肾组织氧化应激和 PKC 活性增加以及 TGFβ1 过度表达有关。